Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
STK11 mutation
i
Other names:
Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6794
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
nivolumab
Resistant: B - Late Trials
nivolumab
Resistant
:
B
nivolumab
Resistant: B - Late Trials
nivolumab
Resistant
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
DRP-104
Sensitive: B - Late Trials
DRP-104
Sensitive
:
B
DRP-104
Sensitive: B - Late Trials
DRP-104
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
durvalumab
Resistant: B - Late Trials
durvalumab
Resistant
:
B
durvalumab
Resistant: B - Late Trials
durvalumab
Resistant
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
ABCP
Sensitive: B - Late Trials
ABCP
Sensitive
:
B
ABCP
Sensitive: B - Late Trials
ABCP
Sensitive
:
B
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
BGB324
Sensitive: B - Late Trials
BGB324
Sensitive
:
B
BGB324
Sensitive: B - Late Trials
BGB324
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + BGB324
Sensitive: B - Late Trials
pembrolizumab + BGB324
Sensitive
:
B
pembrolizumab + BGB324
Sensitive: B - Late Trials
pembrolizumab + BGB324
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
STK11 mutation
Solid Tumor
STK11 mutation
Solid Tumor
TNG260
Sensitive: C2 – Inclusion Criteria
TNG260
Sensitive
:
C2
TNG260
Sensitive: C2 – Inclusion Criteria
TNG260
Sensitive
:
C2
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
docetaxel
Resistant: C3 – Early Trials
docetaxel
Resistant
:
C3
docetaxel
Resistant: C3 – Early Trials
docetaxel
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Resistant: C3 – Early Trials
atezolizumab
Resistant
:
C3
atezolizumab
Resistant: C3 – Early Trials
atezolizumab
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
camrelizumab + rivoceranib
Sensitive: C3 – Early Trials
camrelizumab + rivoceranib
Sensitive
:
C3
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
cetuximab + avelumab
Resistant: C3 – Early Trials
cetuximab + avelumab
Resistant
:
C3
cetuximab + avelumab
Resistant: C3 – Early Trials
cetuximab + avelumab
Resistant
:
C3
STK11 mutation
Lung Adenocarcinoma
STK11 mutation
Lung Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
durvalumab
Resistant: C3 – Early Trials
durvalumab
Resistant
:
C3
STK11 mutation
Cervical Cancer
STK11 mutation
Cervical Cancer
anlotinib + sintilimab
Resistant: C3 – Early Trials
anlotinib + sintilimab
Resistant
:
C3
anlotinib + sintilimab
Resistant: C3 – Early Trials
anlotinib + sintilimab
Resistant
:
C3
STK11 mutation
Solid Tumor
STK11 mutation
Solid Tumor
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive: C3 – Early Trials
pembrolizumab + ramucirumab
Sensitive
:
C3
pembrolizumab + ramucirumab
Sensitive: C3 – Early Trials
pembrolizumab + ramucirumab
Sensitive
:
C3
STK11 mutation
Pituitary Gland Carcinoma
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant: C4 – Case Studies
temozolomide + capecitabine
Resistant
:
C4
temozolomide + capecitabine
Resistant: C4 – Case Studies
temozolomide + capecitabine
Resistant
:
C4
STK11 mutation
Pituitary Gland Carcinoma
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
STK11 mutation
Pancreatic Cancer
STK11 mutation
Pancreatic Cancer
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
everolimus
Sensitive: C4 – Case Studies
everolimus
Sensitive
:
C4
STK11 mutation
Lung Non-Small Cell Squamous Cancer
STK11 mutation
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
pembrolizumab
Resistant: C4 – Case Studies
pembrolizumab
Resistant
:
C4
STK11 mutation
Lung Adenocarcinoma
STK11 mutation
Lung Adenocarcinoma
abemaciclib
Sensitive: C4 – Case Studies
abemaciclib
Sensitive
:
C4
abemaciclib
Sensitive: C4 – Case Studies
abemaciclib
Sensitive
:
C4
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
APG-115
Sensitive: D – Preclinical
APG-115
Sensitive
:
D
APG-115
Sensitive: D – Preclinical
APG-115
Sensitive
:
D
STK11 mutation
Lung Cancer
STK11 mutation
Lung Cancer
dasatinib + selumetinib + RTB101
Sensitive: D – Preclinical
dasatinib + selumetinib + RTB101
Sensitive
:
D
dasatinib + selumetinib + RTB101
Sensitive: D – Preclinical
dasatinib + selumetinib + RTB101
Sensitive
:
D
STK11 mutation
Lung Cancer
STK11 mutation
Lung Cancer
dasatinib
Resistant: D – Preclinical
dasatinib
Resistant
:
D
dasatinib
Resistant: D – Preclinical
dasatinib
Resistant
:
D
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
sirolimus
Sensitive: D – Preclinical
sirolimus
Sensitive
:
D
sirolimus
Sensitive: D – Preclinical
sirolimus
Sensitive
:
D
STK11 mutation
Non Small Cell Lung Cancer
STK11 mutation
Non Small Cell Lung Cancer
CI-1040
Sensitive: D – Preclinical
CI-1040
Sensitive
:
D
CI-1040
Sensitive: D – Preclinical
CI-1040
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login